{"url_path":"/sec/lsta/8-k/2026-07-17/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-17","source_url":"https://www.sec.gov/Archives/edgar/data/320017/0001140361-26-028763-index.html","accession_number":"0001140361-26-028763","cik":"0000320017","ticker":"LSTA","issuer_name":"LISATA THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/320017/0001140361-26-028763-index.html","primary_entity_key":"0000320017","primary_entity_name":"LISATA THERAPEUTICS, INC."},"word_count":324,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n(d) Exhibits.\n\nNumber\n\n \n\n Description of Exhibit\n\n \n\n \n\n[2.1](ef20078177_exhibit2-1.htm)\n\n \n\nAmendment to Agreement and Plan of Merger, dated July 16, 2026, by and among Parent, Purchaser and the Company\n\n \n\n \n\n \n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\nAdditional Information and Where to Find It\n\nA tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, was filed with the SEC by Parent and Purchaser,\nand a Solicitation / Recommendation Statement on Schedule 14D-9 was filed with the SEC by the Company. The offer to purchase shares of Company common stock is being made pursuant to the offer to purchase, the letter of transmittal and related\ndocuments filed as a part of the Schedule TO. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT AND THE SOLICITATION / RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO\nTIME BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR COMMON STOCK, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER. Investors and security\nholders may obtain a free copy of these statements and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Information Agent for the Offer, which is named in the tender offer\nstatement. Investors may also obtain, at no charge, the documents filed or furnished to the SEC by the Company under the “Investors” section of the Company’s website at lisata.com.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be\nsigned on its behalf by the undersigned hereunto duly authorized.\n\nLISATA THERAPEUTICS, INC.\n\n \n\nBy:\n\n/s/ David J. Mazzo\n\nName: David J. Mazzo, PhD\n\nTitle: President and Chief Executive Officer\n\nDated: July 17, 2026"}